Open AccessOverexpression of deubiquitinating enzyme USP 28 promoted non‐small cell lung cancer growth
Author(s) -
Zhang Lei,
Xu Biao,
Qiang Yong,
Huang Hairong,
Wang Changtian,
Li Demin,
Qian Jianjun
Publication year - 2015
Publication title -
journal of cellular and molecular medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.44
H-Index - 130
eISSN - 1582-4934
pISSN - 1582-1838
DOI - 10.1111/jcmm.12426
Subject(s) - deubiquitinating enzyme , cancer research , cell growth , lung cancer , messenger rna , immunohistochemistry , apoptosis , biology , transfection , microbiology and biotechnology , medicine , ubiquitin , oncology , gene , immunology , biochemistry
Non‐small cell lung cancer ( NSCLC ) accounts for most lung cancer. To develop new therapy required the elucidation of NSCLC pathogenesis. The deubiquitinating enzymes USP 28 has been identified and studied in colon and breast carcinomas. However, the role of USP 28 in NSCLC is unknown. The level mRNA or protein level of USP 28 were measured by qRT ‐ PCR or immunohistochemistry ( IHC ). The role of USP 28 in patient survival was revealed by K aplan– M eier plot of overall survival in NSCLC patients. USP 28 was up or down regulated by overexpression plasmid or si RNA transfection. Cell proliferation and apoptosis was assayed by MTT and FACS separately. Potential micro RNA s, which targeted USP 28, were predicated by bioinformatic algorithm and confirmed by D ual L uciferase reporter assay system. High mRNA and protein level of USP 28 in NSCLC were both correlated with low patient survival rate. Overexpression of USP 28 promoted NSCLC cells growth and vice versa. Down‐regulation of USP 28 induced cell apoptosis. USP 28 was targeted by miR‐4295. Overexpression of USP 28 promoted NSCLC cells proliferation, and was associated with poor prognosis in NSCLC patients. The expression of USP 28 may be regulated by miR‐4295. Our data suggested that USP 28 was a tumour‐promoting factor and a promising therapeutic target for NSCLC .